Intel stock spikes after report of possible US government stake
On Tuesday, BofA Securities maintained its Underperform rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a steady price target of $248.00, notably below the current trading price of $300.92. According to InvestingPro data, the stock has delivered a remarkable 42.32% return over the past year, despite showing a tendency to move opposite to broader market trends with a beta of -0.92. The firm’s analyst, Alexandria Hammond, provided insights following Madrigal’s investor call which discussed the 2-year study results of Rezdiffra in compensated MASH cirrhosis. The study was presented at the European Association for the Study of the Liver (EASL) conference over the weekend.
During the investor call, Madrigal highlighted "positive improvements across several imaging/biomarker tests" with its THR-beta agonist, suggesting a potential expansion opportunity in cirrhotic disease. The company’s strong financial position, with a current ratio of 5.91 and more cash than debt on its balance sheet, provides substantial runway for continued development. While acknowledging the encouraging signs and supportive expert feedback from EASL, the analyst expressed difficulty in assessing the overall benefit and identifying which subpopulation might respond best to Rezdiffra. This uncertainty, according to the analyst, is likely the reason for the muted investor reaction post-conference.
Hammond noted that while Madrigal’s drug could play a significant role in the treatment of F4 MASH, the current lack of de-risking factors contributes to the perception of downside risks. The commentary underscores a cautious stance on the pharmaceutical company’s prospects pending further evidence to mitigate these risks.
The analyst’s reiteration of the Underperform rating and price target reflects a continuation of BofA Securities’ previous outlook on Madrigal Pharmaceuticals. The firm’s stance remains unchanged despite the recent data presented and discussions at the EASL conference.
Madrigal Pharmaceuticals has not issued any public response to the analyst’s comments or the maintained Underperform rating and price target. The company’s stock performance will continue to be observed in relation to its clinical developments and the evolving market sentiment.
In other recent news, Madrigal Pharmaceuticals reported a strong performance for the first quarter of 2025, with earnings per share (EPS) and revenue exceeding analyst forecasts. The company posted an EPS of -3.32, outperforming the expected -3.86, and reported revenue of $137.3 million, surpassing the forecasted $112.54 million. This marks a 33% increase in revenue compared to the previous quarter, driven by the success of their product, ResDiffera. Madrigal’s cash reserves remain robust at $848.1 million, providing a solid foundation for future operations.
Additionally, Madrigal Pharmaceuticals is preparing for a potential European launch of ResDiffera in the second half of 2025. The company is also exploring opportunities for business development in the NASH treatment space. The anticipated European launch reflects Madrigal’s strategic focus on expanding its market presence. Analyst firms have not provided any recent upgrades or downgrades for Madrigal Pharmaceuticals, but the company’s strong performance and future prospects have been noted.
Madrigal’s strategic initiatives include enhancing product adoption and expanding market penetration, which have resulted in treating over 17,000 patients. The company is also focusing on potential GLP-1 combination scenarios to improve treatment efficacy. These developments highlight Madrigal Pharmaceuticals’ continued growth and commitment to addressing unmet needs in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.